Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reparixin in Pancreatic Islet Transplantation
NCT01817959Phase 3Completed
- Sponsor
- Dompé
- Start
- Oct 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Reparixin group with Placebo group (2 arms). Primary endpoint: Area Under the Curve for Serum C-peptide Level During the First 2 Hours of an MMTT at Day 365. Started Oct 2012; status: completed.
02
Drugs
reparixin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01817959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01817959.